The classification follows a routine cGMP inspection and Pre-Approval Inspection conducted at the Verna, Goa facility in April 2026

Drug maker Cipla on Thursday said the US food & drug regulator US FDA has classified its Goa facility as Voluntary Action Indicated (VAI).

The US Food and Drug Administration (USFDA) had inspected Cipla's Goa facility in April this year, according to a regulatory filing from the company.

"... we hereby notify that the US FDA vide communication dated 10th June 2026 has classified the above referred inspection as Voluntary Action Indicated (VAI)," it said.

A VAI classification indicates that the USFDA will not take or recommend regulatory or enforcement action because the observations do not meet the threshold for action at this time.

The company said the USFDA had conducted a routine current Good Manufacturing Practices (cGMP) inspection along with a Pre-Approval Inspection (PAI) at its manufacturing facility in Verna, Goa, from April 6 to April 17, 2026.

Published on June 11, 2026